1154579-82-4

Basic information

• Product Name: 2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• Synonyms: 2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• CAS NO: 1154579-82-4
• Molecular Formula: C11H14BF2NO2
• Molecular Weight: 241.0421664
• Mol File: 1154579-82-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(1154579-82-4)
• EPA Substance Registry System: 2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(1154579-82-4)

Safety Data

• Hazardous Substances Data: 1154579-82-4(Hazardous Substances Data)

Usage

General Description

2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is a chemical compound that is commonly used in organic synthesis and pharmaceutical research. It is a pyridine derivative that contains fluorine and boron atoms, which make it highly useful in various chemical reactions and processes. The presence of the boron atom allows for the formation of boron-containing molecules, which have significant applications in medicinal chemistry and material science. The compound also has potential uses in the development of new drugs and pharmaceuticals due to its unique chemical structure and reactivity. Overall, 2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is an important chemical reagent with diverse applications in the field of chemistry and pharmaceuticals.

Upstream product

• 89402-44-8 5-bromo-2,3-difluoropyridine 
• 73183-34-3 bis(pinacol)diborane 
• 851386-35-1 2,3-difluoro-5-iodopyridine 
• 89402-43-7 5-chloro-2,3-difluoropyridine 

Relevant articles and documents

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

IMIDAZOLE DERIVATIVES

Disclosed herein are novel imidazole derivative compounds i.e., benzimidazole and aza-benzimidazole derivatives that act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperiipidemia, diabetes mellitus and obesity. Further disclosed are methods of treating various DGAT1 -related diseases, and the use of such imidazole compounds as described herein in the manufacture of a medicament for such treatment.

HETEROARYLOXY QUINAZOLINE DERIVATIVE

Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).